OTCQX:MRVFF - Post by User
Comment by
JohnDDon Aug 13, 2013 10:07pm
222 Views
Post# 21668206
RE:Looks like Pennsaid 2% application now with the FDA
RE:Looks like Pennsaid 2% application now with the FDA
Here is the other part of the SEC filing that refers to a $16.9 reduction in Pennsaid sales.
John
Specialty Pharmaceuticals. Net sales for the nine months ended June 28, 2013 increased $166.9 million, or 22.4%, to $913.2 million, compared with $746.3 million for the nine months ended June 29, 2012. This increase was primarily driven by $88.3 million of sales from the launch of Methylphenidate ER, a $28.6 million increase in net sales of Exalgo, which was aided by the launch of the 32 mg dosage in August 2012, a $19.5 million increase in sales of Oxycodone (API) and oxycodone-containing tablets, and $20.8 million of sales of intrathecal products. The increase in net sales were partially offset by a $16.9 million decrease in sales of other Brands products, primarily Pennsaid®.